[ad_1]
The “Orthopedic Regenerative Surgical Products Market Size, Share & Trends Analysis Report by Product (Allograft, Synthetic, Cell-based, Viscosupplements), by Application, by End Use, by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering.
The global orthopedic regenerative surgical products market size is anticipated to reach USD 5.6 billion by 2030. The market is expected to expand at a notable CAGR of 3.9% from 2022 to 2030.
Companies Mentioned
-
Baxter
-
Zimmer Biomet
-
Stryker
-
Smith+Nephew
-
Allosource
-
Amniox Medical, Inc.
-
Anika Therapeutics, Inc.
-
Vericel Corporation
-
Vsy Biotechnology GmbH
-
Aptissen SA
-
Mimedx
The key factors driving the market growth include the rising geriatric population, orthopedic procedures, research activities, and technological advancements. Osteoarthritis, for instance, has been identified as the leading cause of chronic disability in the geriatric population over the age of 70. The World Health Organization (WHO) has also designated osteoarthritis as a ‘priority disease’ promoting R&D for therapies to treat osteoarthritis and its associated symptoms.
The growth of the market was restrained during the COVID-19 pandemic due to deferred elective surgeries, low volume of patient flow for chronic conditions in clinics and hospitals, decreased sales and marketing activities, quarantine and protocols, and low demand. Vericel Corporation, for example, reported the adverse impact of COVID-19 on its business and operations during 2020. The company registered cancellations of scheduled MACI procedures; its key product used in the repair of cartilage …
Full story available on Benzinga.com
[ad_2]
Source link
